Do analysts rate CDIO or NXTC?

NextCure has a consensus price target of $19.00, indicating a potential upside of 215.09%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NextCure 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend LTRN or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TCRX or CDIO?

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 705.64%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe TScan Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CDIO or LGVN?

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 1,097.60%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer BCDA or CDIO?

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 1,900.00%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cardio Diagnostics (CDIO) Competitors

$2.00 0.00 (0.00%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$2.00 0.00 (-0.25%)

As of 09/16/2026 04:14 PM Eastern

Compare

CDIO vs. NXTC, LTRN, TCRX, LGVN, and BCDA

Should you buy Cardio Diagnostics stock or one of its competitors? Cardio Diagnostics's main competitors and comparable companies include NextCure (NXTC), Lantern Pharma (LTRN), TScan Therapeutics (TCRX), Longeveron (LGVN), and BioCardia (BCDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardio Diagnostics compare to NextCure?

Cardio Diagnostics (NASDAQ:CDIO) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, NextCure had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for NextCure and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat NextCure's score of 0.96 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
NextCure	Positive

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NextCure has a consensus price target of $19.00, indicating a potential upside of 215.09%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cardio Diagnostics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	592.00	-$6.50M	-$2.92	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

NextCure has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
NextCure	N/A	-154.62%	-100.19%

Cardio Diagnostics has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Cardio Diagnostics beats NextCure on 8 of the 15 factors compared between the two stocks.

How does Cardio Diagnostics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lantern Pharma and Lantern Pharma both had 1 articles in the media. Cardio Diagnostics' average media sentiment score of 1.89 beat Lantern Pharma's score of 1.87 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Very Positive
Cardio Diagnostics	Very Positive

Lantern Pharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Lantern Pharma has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Cardio Diagnostics	$10K	592.00	-$6.50M	-$2.92	N/A

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cardio Diagnostics beats Lantern Pharma on 7 of the 11 factors compared between the two stocks.

How does Cardio Diagnostics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

In the previous week, TScan Therapeutics had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.83 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
TScan Therapeutics	Positive
Cardio Diagnostics	Very Positive

TScan Therapeutics currently has a consensus price target of $2.67, indicating a potential upside of 705.64%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe TScan Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TScan Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market.

TScan Therapeutics has a net margin of -1,655.35% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Cardio Diagnostics has lower revenue, but higher earnings than TScan Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.17	-$129.77M	-$0.91	N/A
Cardio Diagnostics	$10K	592.00	-$6.50M	-$2.92	N/A

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TScan Therapeutics beats Cardio Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Longeveron?

Cardio Diagnostics (NASDAQ:CDIO) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Longeveron has a net margin of -1,977.59% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Longeveron	-1,977.59%	-223.19%	-150.20%

In the previous week, Longeveron had 8 more articles in the media than Cardio Diagnostics. MarketBeat recorded 9 mentions for Longeveron and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat Longeveron's score of 0.40 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
Longeveron	Neutral

Cardio Diagnostics has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Cardio Diagnostics has higher earnings, but lower revenue than Longeveron. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	592.00	-$6.50M	-$2.92	N/A
Longeveron	$1.20M	17.76	-$22.70M	-$9.90	N/A

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Longeveron has a consensus target price of $80.00, suggesting a potential upside of 1,097.60%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cardio Diagnostics and Longeveron tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

BioCardia has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

BioCardia has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, meaning that its stock price is 128% more volatile than the broader market.

20.6% of BioCardia shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cardio Diagnostics has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	315.42	-$8.23M	-$0.64	N/A
Cardio Diagnostics	$10K	592.00	-$6.50M	-$2.92	N/A

In the previous week, BioCardia had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for BioCardia and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat BioCardia's score of 1.29 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Positive
Cardio Diagnostics	Very Positive

BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 1,900.00%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioCardia beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.92M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-0.68	14.33	273.86	25.33
Price / Sales	592.00	1,412.17	643.61	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.52	15.13	10.33	6.24
Net Income	-$6.50M	-$22.78M	$3.49B	$358.55M
7 Day Performance	1.01%	-2.54%	-0.84%	-1.20%
1 Month Performance	0.50%	-2.87%	-1.37%	-4.26%
1 Year Performance	-48.19%	37.93%	21.13%	5.47%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	1.0592 of 5 stars	$2.00 flat	N/A	-48.6%	$5.92M	$10K	N/A	1
NXTC NextCure	4.1368 of 5 stars	$6.32 -0.8%	$19.00 +200.8%	+6.5%	$22.80M	N/A	N/A	90	Gap Up
LTRN Lantern Pharma	0.8968 of 5 stars	$1.78 +4.4%	N/A	-52.9%	$22.68M	N/A	N/A	20	Positive News
TCRX TScan Therapeutics	3.3287 of 5 stars	$0.33 +1.8%	$2.67 +715.5%	-80.8%	$22.16M	$10.32M	N/A	100	Gap Up
LGVN Longeveron	2.5436 of 5 stars	$6.94 +1.1%	$80.00 +1,053.6%	-10.9%	$22.12M	$1.20M	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NXTC, LTRN, TCRX, LGVN, and BCDA

How does Cardio Diagnostics compare to NextCure?

Summary

How does Cardio Diagnostics compare to Lantern Pharma?

Summary

How does Cardio Diagnostics compare to TScan Therapeutics?

Summary

How does Cardio Diagnostics compare to Longeveron?

Summary

How does Cardio Diagnostics compare to BioCardia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NXTC, LTRN, TCRX, LGVN, and BCDA

How does Cardio Diagnostics compare to NextCure?

Does the media refer more to CDIO or NXTC?

Do institutionals and insiders believe in CDIO or NXTC?

Do analysts rate CDIO or NXTC?

Which has preferable earnings and valuation, CDIO or NXTC?

Is CDIO or NXTC more profitable?

Which has more risk and volatility, CDIO or NXTC?

Summary

How does Cardio Diagnostics compare to Lantern Pharma?

Do analysts recommend LTRN or CDIO?

Does the media prefer LTRN or CDIO?

Is LTRN or CDIO more profitable?

Which has more risk and volatility, LTRN or CDIO?

Which has higher earnings & valuation, LTRN or CDIO?

Do institutionals & insiders believe in LTRN or CDIO?

Summary

How does Cardio Diagnostics compare to TScan Therapeutics?

Does the media prefer TCRX or CDIO?

Do analysts prefer TCRX or CDIO?

Which has more volatility and risk, TCRX or CDIO?

Is TCRX or CDIO more profitable?

Which has preferable valuation and earnings, TCRX or CDIO?

Do insiders & institutionals hold more shares of TCRX or CDIO?

Summary

How does Cardio Diagnostics compare to Longeveron?

Is CDIO or LGVN more profitable?

Does the media favor CDIO or LGVN?

Which has more volatility & risk, CDIO or LGVN?

Which has stronger earnings & valuation, CDIO or LGVN?

Do institutionals and insiders have more ownership in CDIO or LGVN?

Do analysts prefer CDIO or LGVN?

Summary

How does Cardio Diagnostics compare to BioCardia?

Is BCDA or CDIO more profitable?

Which has more volatility & risk, BCDA or CDIO?

Do insiders and institutionals have more ownership in BCDA or CDIO?

Which has stronger earnings & valuation, BCDA or CDIO?

Does the media favor BCDA or CDIO?

Do analysts prefer BCDA or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools